Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Improving access to, and completion of, hepatitis C treatment

PHE's latest briefing in the 'Turning evidence into practice' series has practical advice for commissioners and services on improving access to, and completion of, hepatitis C treatment. Preventing blood-borne virus transmission is one of the eight good practice outcomes of the national drug strategy and treating hepatitis C infection is a growing priority for the NHS.

Published
17 July 2015
From
Public Health England
Drug Resistance Common Among European Patients With Chronic Hepatitis B

Rates of lamivudine resistance are high among patients with chronic hepatitis B (CHB) infection across Europe, with many patients developing cross-resistance to entecavir, according to a new report.

Published
14 July 2015
From
Medscape
Gilead pills priced at $1,000 a day are found cost-effective

Health insurers that have been reluctant to cover hepatitis C drugs with list prices of $1,000 a daily dose will face more pressure after a report concluding the medications are “cost-effective” given their benefits.

Published
14 July 2015
From
Bloomberg
Leading Canadian researcher calls for inclusion of co-infected people in large HCV clinical trials

Stephen Shafran from the University of Alberta performed a major review of clinical trials of many DAA-containing HCV therapies used for the treatment of HCV mono-infection as well as HIV-HCV co-infection. Cure rates of HCV are “remarkably similar” in HCV mono-infected and co-infected participants who were treated with the same regimen and who have the same strain (genotype) of HCV.

Published
07 July 2015
From
CATIE
The Medicines Patent Pool Releases Independent Feasibility Studies on Hepatitis C and Tuberculosis

As part of its ongoing consultation processes on the possibility of the Medicines Patent Pool (MPP) expanding into other disease areas, the organisation has published independent feasibility studies exploring the case for potential entry into Hepatitis C and Tuberculosis.

Published
07 July 2015
From
Medicines Patent Pool
US: Hepatitis C Rising -- Especially Among Young People -- and May Be Underestimated

While hepatitis C has traditionally been predominant among Baby Boomers, the new report shows that HCV incidence is rising fastest among young people. But a recently published related study suggests that formal surveillance methods may grossly underestimate the number of people newly infected with HCV.

Published
06 July 2015
From
HIVandHepatitis.com
Public health surveillance system may underestimate cases of acute hepatitis C infection

A new study suggests massive under reporting may occur within the system set up by the US Centers for Disease Control and Prevention to estimate the incidence of acute hepatitis C virus infection. A research team found that less than 1 percent of a group of acute HCV patients in Massachusetts had been reported to the CDC, largely because required data was either not available or did not meet CDC definitions for acute HCV infection.

Published
02 July 2015
From
Eurekalert Inf Dis
People with HIV and HCV co-infection who have fibrosis stages F2 and above should be prioritised for new anti-HCV therapies

People with HIV and hepatitis C virus (HCV) co-infection who have advanced liver fibrosis should be prioritised for therapy with new anti-HCV drugs, investigators argue in AIDS.

Published
02 July 2015
By
Michael Carter
National study finds life-threatening barriers in access to breakthrough drugs

Most states violate federal Medicaid law because they deny coverage for sofosbuvir, a new and highly effective treatment to cure hepatitis C, according to Lynn E. Taylor, M.D., director of The Miriam Hospital's HIV/Viral Hepatitis Coinfection Program. Taylor's team of researchers examined Medicaid policies for hepatitis C virus treatment using sofosbuvir and found that most should change policy to improve access to the treatment.

Published
30 June 2015
From
Eurekalert
FDA is Sued by Advocacy Groups That Want Gilead Hepatitis C Trial Data

Specifically, the groups hope to learn about different responses that different patients experienced during clinical trials. Tracy Swan of Treatment Action Group points to relapses in a Harvoni clinical trial that occurred only among African-Americans. The groups also want to perform an independent analysis of poor prognostic factors among people who were not cured in order to identify a patient profile.

Published
29 June 2015
From
Wall Street Journal (blog)

Filter by country